BioXcel Therapeutics annual operating margin
2022
2023
2024
2025
BioXcel Therapeutics's operating margin was −7,859.97% for fiscal 2025.
View full BioXcel Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −7,859.97% | −4892.40 pp |
| 2024 | 2024-12-31 | −2,967.56% | +9480.41 pp |
| 2023 | 2023-12-31 | −12,447.97% | +30124.03 pp |
| 2022 | 2022-12-31 | −42,572.00% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −5,600.55% | +7609.45 pp |
| Q1 2026 | 2026-03-31 | −4,962.62% | +1048.69 pp |
| Q4 2025 | 2025-12-31 | −4,016.41% | −1149.47 pp |
| Q3 2025 | 2025-09-30 | −14,518.37% | −7372.11 pp |
| Q2 2025 | 2025-06-30 | −13,210.00% | −11643.33 pp |
| Q1 2025 | 2025-03-31 | −6,011.31% | −1859.59 pp |
| Q4 2024 | 2024-12-31 | −2,866.94% | +2418.43 pp |
| Q3 2024 | 2024-09-30 | −7,146.26% | +7017.08 pp |
| Q2 2024 | 2024-06-30 | −1,566.67% | +9902.48 pp |
| Q1 2024 | 2024-03-31 | −4,151.72% | +20701.68 pp |
| Q4 2023 | 2023-12-31 | −5,285.37% | +23174.48 pp |
| Q3 2023 | 2023-09-30 | −14,163.34% | — |
| Q2 2023 | 2023-06-30 | −11,469.15% | — |
| Q1 2023 | 2023-03-31 | −24,853.40% | — |
| Q3 2022 | 2022-09-30 | −28,459.85% | — |
Across the available reported history, BioXcel Therapeutics's operating margin decreased from −2,967.56% to −7,859.97%, a change of −4892.40 percentage points. The latest reported quarter, Q2 2026, shows −5,600.55%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioXcel Therapeutics filings at SEC.gov ↗